CTGF Antibody - #DF7091

(7)   (14)  
Product: CTGF Antibody
Catalog: DF7091
Description: Rabbit polyclonal antibody to CTGF
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Sheep, Rabbit
Mol.Wt.: 38kDa; 38kD(Calculated).
Uniprot: P29279
RRID: AB_2839046

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:20-1:50
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(88%), Bovine(100%), Sheep(100%), Rabbit(88%)
Clonality:
Polyclonal
Specificity:
CTGF Antibody detects endogenous levels of total CTGF.
RRID:
AB_2839046
Cite Format: Affinity Biosciences Cat# DF7091, RRID:AB_2839046.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CCN 2; CCN family member 2; CCN2; Connective tissue growth factor; Ctgf; CTGF_HUMAN; Hcs 24; Hcs24; Hypertrophic chondrocyte specific protein 24; Hypertrophic chondrocyte-specific gene product 24; Hypertrophic chondrocyte-specific protein 24; IBP-8; IGF-binding protein 8; IGFBP-8; IGFBP8; Insulin like Growth Factor Binding Protein 8; Insulin-like growth factor-binding protein 8; MGC102839; NOV 2; NOV2;

Immunogens

Immunogen:
Uniprot:

P29279(CCN2_HUMAN) >>Visit HPA database.

Gene(ID):
CTGF(1490)
Expression:
P29279 CCN2_HUMAN:

Expressed in bone marrow and thymic cells. Also expressed one of two Wilms tumors tested.

Description:
The protein encoded by this gene is a mitogen that is secreted by vascular endothelial cells. The encoded protein plays a role in chondrocyte proliferation and differentiation, cell adhesion in many cell types, and is related to platelet-derived growth factor. Certain polymorphisms in this gene have been linked with a higher incidence of systemic sclerosis. [provided by RefSeq, Nov 2009]
Sequence:
MTAASMGPVRVAFVVLLALCSRPAVGQNCSGPCRCPDEPAPRCPAGVSLVLDGCGCCRVCAKQLGELCTERDPCDPHKGLFCHFGSPANRKIGVCTAKDGAPCIFGGTVYRSGESFQSSCKYQCTCLDGAVGCMPLCSMDVRLPSPDCPFPRRVKLPGKCCEEWVCDEPKDQTVVGPALAAYRLEDTFGPDPTMIRANCLVQTTEWSACSKTCGMGISTRVTNDNASCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKISKPIKFELSGCTSMKTYRAKFCGVCTDGRCCTPHRTTTLPVEFKCPDGEVMKKNMMFIKTCACHYNCPGDNDIFESLYYRKMYGDMA

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Bovine
100
Sheep
100
Pig
88
Rabbit
88
Chicken
75
Horse
0
Dog
0
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P29279 As Substrate

Site PTM Type Enzyme
K91 Ubiquitination
S118 Phosphorylation
Y122 Phosphorylation
S145 Phosphorylation
T193 O-Glycosylation
T219 Phosphorylation
T222 Phosphorylation
S234 Phosphorylation
T322 Phosphorylation
Y340 Phosphorylation

Research Backgrounds

Function:

Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis.

Subcellular Location:

Secreted>Extracellular space>Extracellular matrix. Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in bone marrow and thymic cells. Also expressed one of two Wilms tumors tested.

Subunit Structure:

Monomer.

Family&Domains:

Belongs to the CCN family.

Research Fields

· Environmental Information Processing > Signal transduction > Apelin signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Hippo signaling pathway.   (View pathway)

References

1). Cortex Mori Radicis extract attenuates myocardial damages in diabetic rats by regulating ERS. BIOMEDICINE & PHARMACOTHERAPY, 2017 (PubMed: 28427040) [IF=7.5]

Application: WB    Species: rat    Sample:

Fig. 4. Effects of the Cortex Mori Radicis extract exerts on cardiac fibrosis. a.b. Western blots shows Collagen I and CTGF contents are increased in diabetes states, while the Cortex Mori Radicis extract exerts a decline in their expression. We calculated the fold changes by expressing each normalized value relative to the Control group.The results presented as the mean SEM (n = 3 per group) *p < 0.05 compared with control group; and # p < 0.05, ##p < 0.01 compared with diabetes group.
2). USP21 regulates Hippo signaling to promote radioresistance by deubiquitinating FOXM1 in cervical cancer. Human Cell, 2021 (PubMed: 34825342) [IF=4.3]
3). Anticancer Effect of Puerarin on Ovarian Cancer Progression Contributes to the Tumor Suppressor Gene Expression and Gut Microbiota Modulation. Journal of Immunology Research, 2022 (PubMed: 35935578) [IF=4.1]

Application: WB    Species: Rat    Sample: tumor tissues

Figure 5 Expression of cell proliferation and tumor suppressor genes was regulated by puerarin treatment in OC model rats. (a) Positive expression of Ki67, PCNA, P53, and PTEN in tumor tissues was detected by an immunohistochemistry assay (magnification: ×200). (b) Protein expression levels of P53, P21, PTEN, BRCA1, BIRC5, and CTGF in tumor tissues were detected by Western blot assay, and GAPDH was used as the internal control. OC: ovarian cancer.
4). miR‑101a‑3p overexpression prevents acetylcholine‑CaCl2‑induced atrial fibrillation in rats via reduction of atrial tissue fibrosis, involving inhibition of EZH2. Molecular Medicine Reports, 2021 (PubMed: 34435649) [IF=3.4]

Application: WB    Species: rat    Sample: atrial tissues of heart

Figure 4. |miR‑101a‑3p overexpression attenuates atrial tissue fibrosis in rats with AF.(C) Protein expression levels of TGF‑β1,CTGF, fibronectin and α‑SMA in atrial tissues of heart were assessed via western blotting. The results are presented as the mean ± standard deviation (n=6). ###P<0.001 vs. sham group; **P<0.01 and ***P<0.001 vs. AF + LV‑NC group. CTGF, connective tissue growth factor; α‑SMA, α‑smooth muscle actin; AF, atrial fibrillation; LV‑NC, lentivirus negative control; miR, microRNA.

Application: WB    Species: Rat    Sample: atrial tissues

Figure 4. miR-101a-3p overexpression attenuates atrial tissue fibrosis in rats with AF. Expression levels of (A) collagen I and (B) collagen III in atrial tissues of heart were determined via immunohistochemistry. At the same time, quantitative analysis was carried out. (C) Protein expression levels of TGF-β1, CTGF, fibronectin and α-SMA in atrial tissues of heart were assessed via western blotting. The results are presented as the mean ± standard deviation (n=6). ###P<0.001 vs. sham group; **P<0.01 and ***P<0.001 vs. AF + LV-NC group. CTGF, connective tissue growth factor; α-SMA, α-smooth muscle actin; AF, atrial fibrillation; LV-NC, lentivirus negative control; miR, microRNA.
5). Yes-Associated Protein is Involved in Myocardial Fibrosis in Rats with Diabetic Cardiomyopathy. Diabetes, Metabolic Syndrome and Obesity, 2021 (PubMed: 34012279) [IF=3.3]

Application: IHC    Species: Rat    Sample: myocardium

Figure 2 HE staining, CTGF, Profilin-1, and PAI-1 protein expression in the myocardium in vivo (n=6). (A-D) Representative HE staining and immunohistochemical staining of CTGF, Profilin-1 and PAI-1 in the 4 groups (scale bar=20 μm). (E-H) Quantitative analysis of CTGF, Profilin-1, and PAI-1 protein expression. *P

Application: WB    Species: Rat    Sample: myocardium

Figure 5 YAP expression and fibrosis levels in CFs in vitro (n=5). (A) Western blot analysis of YAP protein expression stimulated by high glucose (25 mM) at different time points. (B) Western blot analysis of YAP, CTGF and fibronectin protein expression in CFs transfected with YAP-shRNA or scramble-shRNA. (C) Quantitative analysis of YAP protein expression shown in (A). (D) YAP mRNA expression in CFs transfected with YAP-shRNA or Scramble-shRNA. (E–G) Quantitative analysis of YAP, CTGF and fibronectin protein expression shown in (B). *P
6). Upregulation of Angiomotin-like 2 ameliorates experimental pulmonary arterial hypertension by inactivating YAP1 signaling. Journal of cardiovascular pharmacology, 2022 (PubMed: 39027975) [IF=3.0]
7). MiR-133a-3p inhibits scar formation in scalded mice and suppresses the proliferation and migration of scar derived-fibroblasts by targeting CTGF. EXPERIMENTAL ANIMALS, 2021 (PubMed: 33658464) [IF=2.4]

Application: WB    Species: Mice    Sample: scar tissue

Fig. 3. MiR-133a-3p attenuated the expression of fibrosis-related proteins in scar tissue of scalded mice. (A) Western blot analysis for α-smooth muscle actin (α-SMA), collagen I, transforming growth factor (TGF)-β1 and connective tissue growth factor (CTGF). The relative expression of (B) α-SMA, (C) collagen I, (D) TGF-β1 and (E) CTGF. Data were shown as mean value ± SD (n=6). ***P<0.001, versus Control group. &&P<0.01, &&&P<0.001, versus NC agomir group.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.